Dicarboxylic acids and derivatives
Search Within Results
1
–
1
of
1
results
1
![Medchemexpress LLC Urea, N-[1-[(2-amino-4-pyridinyl)methyl]-1H-indol-4-yl]-N'-(5-bromo-2-methoxyphenyl)- | 900573-88-8 | 99.0% | 466.33 | 1 ML](https://assets.fishersci.com/TFS-Assets/CCG/product-images/default.jpg-250.jpg)
Medchemexpress LLC Urea, N-[1-[(2-amino-4-pyridinyl)methyl]-1H-indol-4-yl]-N'-(5-bromo-2-methoxyphenyl)- | 900573-88-8 | 99.0% | 466.33 | 1 ML
JI-101 is an orally available multi-kinase inhibitor that targets VEGFR2, PDGFRβ, and EphB4. It exhibits potent anti-cancer activity and has been studied for its pharmacokinetics and tissue distribution. The compound is stable in preclinical and human liver microsomes, with relatively higher metabolism in mice compared to dog, human, and rat liver microsomes. Following oral administration, JI-101 is rapidly absorbed, reaching peak concentration within 2 hours, and has an oral bioavailability of 55%. Its primary elimination route is through feces, and it undergoes extensive tissue distribution, with preferential uptake into lung tissue.
- Orally available
- Multi-kinase inhibitor, targeting VEGFR2, PDGFRβ, and EphB4
- Potent anti-cancer activity
- Stable in preclinical and human liver microsomes
- Rapidly absorbed after oral administration
- Extensive tissue distribution, with preferred uptake in lung tissue
